scholarly journals Treatment With Cholecalciferol Leads to Increase Of Selected Semen Parameters in Young Infertile Males: Results of a 6-month Interventional Study

2021 ◽  
pp. S99-S107
Author(s):  
I. Bartl ◽  
M. Ondrušová ◽  
M. Kužma ◽  
P. Jackuliak ◽  
A. Gažová ◽  
...  
Keyword(s):  
Vitamin D ◽  
Semen Analysis ◽  
Sperm Concentration ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Sperm Parameters ◽  
Semen Parameters ◽  
Serum Vitamin D ◽  
Vitamin D Levels

High incidence of infertility along with low vitamin D levels was detected in otherwise healthy young men. The aim is to observe the effect of vitamin D supplementation on semen parameters as assessed by semen analysis in infertile men. In total, 45 men (mean age 36.6 years) in consecutive order were included, of whom 34 finished the study. Subjects were supplemented by vitamin D (cholecalciferol) 2500 IU/day. Vitamin D levels were assessed by HPLC. Semen analysis was performed strictly following 2010 WHO guidelines. Study periods were baseline and month 6. During follow-up, 20 %, 7.4 %, 22 % and 0.7 % increase in serum vitamin D levels, progressive sperm motility, sperm concentration and sperm morphology, respectively, were observed (all p<0.05). At follow-up end, 9 patients (26 %) reached normal sperm parameters of whom 2 fertilized their partner. There was no correlation between vitamin D and semen parameters observed. This study proves that vitamin D supplementation is possibly a modulator of sperm parameters in vitamin D deficient, otherwise healthy men. Although a direct relationship between vitamin D and sperm parameters was not observed obtaining adequate vitamin D levels could likely play a role in the male factor of infertility.

Do serum vitamin D levels correlate with semen analysis parameters and sperm DNA fragmentation?

2012 ◽  
Vol 98 (3) ◽  
pp. S47-S48
Author(s):  
L. Rubal ◽  
A.M. Hernandez ◽  
S. Ingles ◽  
M. Scrooc ◽  
K. Bendikson
Keyword(s):  
Vitamin D ◽  
Dna Fragmentation ◽  
Semen Analysis ◽  
Serum Vitamin ◽  
Sperm Dna Fragmentation ◽  
Serum Vitamin D ◽  
Sperm Dna ◽  
Vitamin D Levels

Association Between cardiometabolic risk factor and responsiveness to vitamin D supplementation: A New Approach using Artificial Neural Network analysis

2020 ◽  
Author(s):  
Elahe Allahyari ◽  
Parichehr Hanachi ◽  
Seyed Jamal Mirmoosavi ◽  
Gordon A. Ferns ◽  
Afsane Bahrami ◽  
...  
Keyword(s):  
Vitamin D ◽  
Risk Factor ◽  
Cardiometabolic Risk ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Cardiometabolic Risk Factor ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Artificial Neural

Abstract BackgroundAccumulating data have highlighted the prominence of supplementation as an effective approach for vitamin D deficiency. But individuals vary in their response to vitamin D supplementation. In this study, the effect of cardiometabolic risk factors were evaluate on magnitude of response to vitamin D supplementation by using novel statistical analysis, artificial neural networks(ANNs).Methods608 participants aged between 12 to 19 years old were assed in this prospective interventional study. Nine vitamin D capsules containing 50000IU vitamin D/weekly were given to all participants over the 9 week period. The change in serum 25(OH)D level was calculated as the difference between post-supplementation and basal levels. Suitable ANNs model were selected between different algorithms in the hidden and output layers and different numbers of neurons in the hidden layer. Then, the major determinants in predicting response to vitamin D supplementations were identified (Trial registration: IRCT201509047117N7; 2015-11-25; Retrospectively registered)ResultsSigmoid in both hidden and output layers with 4 hidden neurons had acceptable sensitivity, specificity and accuracy area under the ROC curve in our study. Baseline serum vitamin D (30.4%), waist to hip ratio (10.5%), BMI (10.5%), systolic blood pressure (8%), heart rate (6.4%), and waist circumference (6.1%) were the greatest importance in predicting the response in serum vitamin D levels. ConclusionWe provide the first attempt to relate anthropometric specific recommendations to attain serum vitamin D targets. With the exception of cardiometabolic risk factor, the relative importance of other factors and the mechanisms by which these factors may affect the response requires further analysis in future studies.

scholarly journals A170 VITAMIN D IN IBD PATIENTS – A RETROSPECTIVE REVIEW

2020 ◽  
Vol 3 (Supplement_1) ◽  
pp. 35-36
Author(s):  
R A MacMillan ◽  
T Ponich
Keyword(s):  
Vitamin D ◽  
Bone Density ◽  
Disease Severity ◽  
Regression Coefficient ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Serum Vitamin D ◽  
Mayo Score ◽  
Vitamin D Levels ◽  
Low Serum

Abstract Background Vitamin D is a critical factor in bone remodelling, calcium absorption and may promote anti-inflammatory cytokines in the gut. Inflammatory bowel disease (IBD) is associated with a reduction in serum Vitamin D levels and a chronic inflammatory state, both of which are strong risk factors for bone density loss affecting IBD patients. Despite European and North American IBD maintenance guidelines for Vitamin D monitoring and bone density scans, there are limited North American investigations into factors influencing serum Vitamin D levels in the IBD patient population specifically. Aims We investigated whether patient demographics, disease severity indexes and/or inflammatory markers were linked to low serum Vitamin D levels in our IBD patients. We also established the extent of Vitamin D serum deficiencies and supplementation rates in our IBD patients. Methods A retrospective chart review of a single clinician’s practice at London Health Science Centre, Victoria Hospital, over the past 20 months, was performed to: 1) assess the frequency of low serum 25-OH Vitamin D (25-OH D) in the IBD patient population and 2) determine whether patient disease severity was linked to lower 25-OH D levels. A multivariate regression analysis was performed assessing Crohn’s Disease (CD) or Ulcerative Colitis (UC) patient factors: age, sex, disease duration, seasonality, current pharmacologic treatments, past surgeries, CD Activity Index, UC Mayo score, C-reactive protein, and fecal calprotectin (Fcal) level. Results 175 IBD patients had at least one 25-OH D measurement with 71 patients actively on Vitamin D therapy. Of UC and CD patients who were not on Vitamin D therapy, 63% (17/27) and 79% (61/77) were 25-OH D deficient, respectively. 25-OH D levels in the CD population was associated with Vitamin D supplementation (regression coefficient [RC] 23.99, 95% confidence interval [CI] 14.54 to 33.45), summer season ([RC] 9.90, [CI] 0.56 to 19.24), and past bowel resection ([RC] -10.61, [CI] -20.48 to -0.76). 25-OH D levels in the UC population was associated with Vitamin D supplementation (regression coefficient [RC] 47.23, 95% confidence interval [CI] 27.62 to 66.83), and Mayo severity scores ([RC] -23.01, [CI] -41.82 to -4.20). Fcal (78 patients) was inversely associated with 25-OH D levels but the trend was not significant. Conclusions Overall, 25-OH D levels were lower in both the UC and CD patient populations relative to the already deficient Canadian population. However, IBD patients are responsive to Vitamin D supplementation. Tools with more objective evidence of disease severity such as UC Mayo score and fcal should be prioritized for identifying the IBD population requiring supplementation. Funding Agencies None

scholarly journals Role of Vitamin D in Parkinson’s Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-11 ◽  
Author(s):  
Khanh Lương ◽  
Lan Nguyễn
Keyword(s):  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Mhc Class Ii ◽  
Serum Vitamin ◽  
Renin Angiotensin System ◽  
Vitamin D Supplementation ◽  
Heme Oxygenase 1 ◽  
Serum Vitamin D ◽  
Vitamin D Levels

Parkinson’s disease (PD) is the second most common form of neurodegeneration in the elderly population. Clinically, it is characterized by tremor, rigidity, slowness of movement, and postural imbalance. A significant association between low serum vitamin D and PD has been demonstrated, suggesting that elevated vitamin D levels might provide protection against PD. Genetic studies have helped identify a number of proteins linking vitamin D to PD pathology, including the major histocompatibility complex (MHC) class II, the vitamin D receptor (VDR), cytochrome P450 2D6 (CYP2D6), chromosome 22, the renin-angiotensin system (RAS), heme oxygenase-1 (HO-1), poly(ADP-ribose) polymerase-1 gene (PARP-1), neurotrophic factor (NTF), and Sp1 transcription factor. Vitamin D has also been implicated in PD through its effects on L-type voltage-sensitive calcium channels (L-VSCC), nerve growth factor (NGF), matrix metalloproteinases (MMPs), prostaglandins (PGs) and cyclooxygenase-2 (COX-2), reactive oxygen species (ROS), and nitric oxide synthase (NOS). A growing body of evidence suggests that vitamin D supplementation may be beneficial for PD patients. Among the different forms of vitamin D, calcitriol (1,25-dihydroxyvitamin D3) is best indicated for PD, because it is a highly active vitamin D3 metabolite with an appropriate receptor in the central nervous system (CNS).

ID: 86: SAFETY OF 50,000-100,000 UNITS OF VITAMIN D3 PER WEEK IN VITAMIN D DEFICIENT, HYPERCHOLESTEROLEMIC PATIENTS, WITH STATIN INTOLERANCE

2016 ◽  
Vol 64 (4) ◽  
pp. 929.2-930
Author(s):  
V Jetty ◽  
G Duhon ◽  
P Shah ◽  
M Prince ◽  
K Lee ◽  
...  
Keyword(s):  
Vitamin D ◽  
Serum Calcium ◽  
Vitamin D3 ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
High Serum ◽  
Statin Intolerance ◽  
Serum Vitamin D ◽  
Median Serum

BackgroundIn ∼85–90% of statin intolerant patients, vitamin D deficiency (serum 25 (OH) D <32 ng/ml) is a reversible cause of statin intolerance, usually requiring 50,000 to 100,000 units of vitamin D/week continuously to normalize serum vitamin D, and thus successfully allow reinstitution of statins which previously could not be tolerated because of myalgia-myositis.Specific AimIn 274 statin intolerant patients, all with low entry serum vitamin D (<32 ng/ml, median 21 ng/ml), we assessed safety and efficacy of vitamin D supplementation (50,000–100,000 units/week) over treatment periods of 3 months (n=274), 3 and 6 months (n=161), 3, 6, and 9 months (n=58), and 3, 6, 9, and 12 months (n=22).ResultsIn the 385 patients with 3 month follow-up, taking mean 61,000 and median 50,000 IU of vitamin D3/week, median serum vitamin D rose from 20 to 42 ng/ml (p<0.0001); vitamin D became high (>100 ng/ml) but not toxic-high (>150 ng/ml) in 4 patients (1.0%) (101, 102, 106, 138 ng/ml). Median serum calcium was unchanged from entry (9.6 mg/dl) to 9.6 at 3 months. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or from high-to-normal did not significantly differ (McNemar S=1.0, p=0.32), and there was no significant trend in change of the calculated glomerular filtration rate (eGFR) from entry to follow-up (McNemar S=2.6, p=0.11).In the 161 patients with 3 and 6 month follow-up, taking mean 67,000 and median 50,000 IU of vitamin D3/week, median entry serum vitamin D rose from 21 to 42 to 44 ng/ml (p<0.0001), serum vitamin D was high (>100 but <150 ng/ml) in 2 patients at 3 months (1.2%, 101, 102 mg/ml) and in 3 (1.9%) at 6 months (101, 140, 140 ng/ml). Median serum calcium was unchanged from entry (9.7 mg/dl), at 3 and 6 months (9.7, 9.6 mg/dl, p>0.05). On vitamin D supplementation, the change in serum calcium from normal-to-high or high-to-normal was no significant trend (McNemar S=0.7, p=0.41), and no trend in change of eGFR (McNemar S=1.3, p=0.26).In the 58 patients with 3, 6, and 9 month follow-up on mean and median 71,000 and 100,000 IU of D3/week, median entry vitamin D rose from 20 to 37, 41, and 44 ng/ml (p<0.0001), with 1 (1.7%, 102 ng/ml), 2 (3.5%, 140, 140 ng/ml), and 0 (0%) patients high. Median serum calcium was unchanged from entry, median 9.7, 9.8, 9.6, and 9.6 mg/dl. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or high-to-normal was not significant (McNemar S=1.8, p=0.18), and no trend in change of eGFR (McNemar S=2, p=0.16).In the 22 patients with follow-up at 3, 6, 9, and 12 months on mean and median 70,000 and 75,000 IU of D3/week, median serum vitamin D rose from 20 to 37, to 41, to 44, and to 43 ng/ml (p<0.0001), with 1 (5%, 102 ng/ml) high, 2 (9%, 140, 140) high, 0 (0%) high, and 1 (5%, 126 ng/ml) high. Serum calcium was unchanged, median at entry 9.6, and then at 3, 6, 9, and 12 months 9.7, 9.7, 9.5, and 9.7 mg/ml. At entry serum calcium was normal in 21, none high, and one became high at 12 month follow-up. The trend of change in eGFR was insignificant, McNemar S=1.0, p=0.32.When serum D rose above 100 ng/ml in the few cases, as above, it fell into the normal range within 2 weeks by reducing the vitamin D dose by 50%.ConclusionsWhen 50,000–100,000 units of vitamin D/week are given to reverse statin intolerance in statin intolerant patients with low entry vitamin D (<32 ng/ml), it appears to be safe over up to 1 year follow-up, without toxic high serum vitamin D levels >150 ng/ml, and levels rarely >100 ng/ml, and without changes in serum calcium or eGFR.

scholarly journals Evaluation of efficacy of a nanoparticle based vitamin D formulation in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D

2017 ◽  
Vol 3 (3) ◽  
pp. 486
Author(s):  
Kishore A. Manek
Keyword(s):  
Vitamin D ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Open Label ◽  
Baseline Serum ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Post Marketing ◽  
Sufficient Vitamin ◽  
To Receive

<p><strong>Background:</strong> In India more than 90% of apparently healthy Indians have subnormal 25(OH) D levels. To maintain sufficient vitamin D level, apart from sunlight and food containing vitamin D, supplementation with vitamin D is also required. The objective of this study was to find out effectiveness of nanoparticle based vitamin D formulations in patient of vitamin D deficiency and insufficiency</p><p><strong>Methods:</strong> This was a prospective, open label, single arm, non-comparative, dose response post-marketing efficacy study (PMS) – phase-4 study to find the effectiveness of a nanoparticle based vitamin D formulation in adult patients between 18 to 65 years of either gender, attending/visiting the study site with documented deficiency or insufficiency of vitamin D (&lt;30 ng/ml) or sign and symptoms of deficiency or insufficiency of vitamin D. Each subject planned to receive 60,000 IU of nanoparticle based vitamin D, once weekly, for 8 weeks orally. Serum 25(OH) D levels were measured at baseline, 4 and 8 week.</p><p><strong>Results:</strong> The mean baseline serum 25[OH] D levels were 15.90. After treatment with nanoparticle based vitamin D there was a significant increase in the serum vitamin D levels at 4 weeks (41.03) and 8 weeks (31.38) (p&lt;0.0001). Patients who have received treatment for at least 4 weeks’ period (n=38), the improvement (serum 25[OH] D &gt;30 ng/ml) was seen in 84.2% patients (n=32) at the end of 4 weeks itself. There is significant increased (&lt;0.0001) in the physical component scores of the SF-12 QOL questionnaire after 8 weeks of therapy.</p><p><strong>Conclusions:</strong> Nanoparticle based formulation of vitamin D<sub>3</sub> is effective and safe in correction of vitamin D levels in patients with documented deficiency or insufficiency of vitamin D. Also the safety and tolerability is well accepted and reported good to excellent by patients and physician.</p><p> </p>

scholarly journals Influence of Supplementary Vitamin D on the Prognostic Pathway of Type1 Diabetes Among Children

2021 ◽  
Vol 14 (1) ◽  
pp. 303-309
Author(s):  
Mostafa Hassan Ragab ◽  
Eman Monir Sherif ◽  
Nadia Badawy Abd- El Gawad ◽  
Safaa Mohamed Elserougy ◽  
Eman Essam Shaban ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Oral Vitamin ◽  
Intake Assessment ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Egyptian Children ◽  
The Impact

Diabetes is one of the commonest chronic diseases worldwide. Vitamin D deficiency showed to be increasing, and have a potential role in autoimmune diseases among which in type 1 diabetes. The aim The aim of the study was to assess the impact of oral vitamin D supplementation on blood glucose (HbA1C) in T1DM patients and to find out the role of vitamin D as a biomarker for follow of T1DM patients compared to HbA1C. Subjects and methods: A randomized interventional clinical study was designed. The study enrolled 60 children patients with T1DM. Only 45 children continued to the end of study. Initial (pre-intake) assessment included history taking, clinical examination, and measurement of serum 25-OH vitamin D3 and serum HbA1C. These children received oral vitamin D supplements for 3 months then post-intake assessment were done again. Results: The study showed that serum vitamin D was deficient among Egyptian children and adolescents with T1DM (mean 11.4±3.4 ng/ml). , 53.33% of the patients had vitamin D deficiency with a 35.6% had insufficiency and 11.11% were VD sufficient. Patients received oral vitamin D supplementation for 3 months after which marked improvement in the levels of serum vitamin D levels and HA1C, 87.5% and 86.5% respectively.

Investigation of Vitamin D Levels in Children Aged 0–4 Years in Yunnan Province

2021 ◽  
Author(s):  
Yuqin Wu ◽  
Yanfei Yang ◽  
Xiao Xiao ◽  
Lin Wang ◽  
Zheng Yin ◽  
...  
Keyword(s):  
Vitamin D ◽  
Young Children ◽  
Yunnan Province ◽  
Serum Vitamin ◽  
Policy Formulation ◽  
Vitamin D Supplementation ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Significant Difference ◽  
Infants And Young Children

Abstract Aim: To investigate the vitamin D levels in children aged 0–4 years in Yunnan Province.Methods: This study selected children aged 0 to 4 years who underwent physical examination in the special needs clinic of the Hospital from October 2019 to December 2020 as subjects to analyze serum 25(OH)D levels.Result: Vitamin D deficiency was more common in girls than in boys. There was no significant difference in serum vitamin D levels between boys and girls at any age. However, there was a significant decrease in vitamin D levels after 2 years old in all chidren at all ages. The levels of vitamin D in children were highest in summer, which were significantly higher than other seasons, and were lowest in winter. At the same time, vitamin D levels were significantly different based on the economic level of cities. The serum vitamin D contents of infants and young children in the top five cities with the highest economic levels were significantly higher than in lower-ranked cities. There was a significant correlation between vitamin D content and serum calcium. Conclusion: This study preliminarily determined a reasonable reference range for serum 25 hydroxyvitamin D content in infants aged 0–4 years in Yunnan Province. Which will be of significance for the establishment of official guidelines on vitamin D supplementation in infants and young children in Yunnan and for policy formulation.

Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2712-2712
Author(s):  
Jennifer L. Kelly ◽  
Gilles Salles ◽  
Bryan H. Goldman ◽  
Richard I Fisher ◽  
Olivier Casasnovas ◽  
...  
Keyword(s):  
Vitamin D ◽  
Follicular Lymphoma ◽  
Prognostic Significance ◽  
Serum Vitamin ◽  
B Cell Lymphoma ◽  
Serum Vitamin D ◽  
Vitamin D Levels ◽  
Pre Treatment ◽  
Anti Cd20

Abstract Abstract 2712 Introduction: While follicular lymphoma (FL) prognosis is known to be influenced by clinical characteristics and age, investigation of modifiable factors in the modern treatment era with prognostic significance has been limited. Binding of the active vitamin D metabolite to the nuclear vitamin D receptor results in autocrine and paracrine effects possibly relevant to both cancer prevention and prognosis, including regulation of cell proliferation, induction of apoptosis and differentiation, and immune modulation. Recent literature reports a potential association between high vitamin D and improved prognosis in multiple myeloma, breast and colorectal cancer, and most recently, diffuse large B cell lymphoma and chronic lymphocytic leukemia. Using stored serum from SWOG and LYSA (formerly GELA) FL trials, we evaluated the impact of pretreatment vitamin D on outcome. Methods: Subjects included in the SWOG cohort were previously untreated FL patients (pts) enrolled on one of three SWOG clinical trials (S9800, S9911, S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or I-131 tositumomab, enrolled 1998–2008); enrolled pts with pre-treatment serum stored and available through the SWOG serum banking protocol (S8947) were eligible for this analysis. Subjects included in our second independent cohort were also previously untreated FL pts enrolled on LYSA's PRIMA trial (rituximab plus chemotherapy, randomized to rituximab maintenance versus observation; enrolled 2004–2007), who had pre-treatment serum samples stored and available for serum 25(OH)D analysis. Baseline samples for both cohorts were sent to the Mayo Clinic Medical Laboratories where 25(OH)D2 and 25(OH)D3was measured directly using the gold standard liquid chromatography-tandem mass spectrometry method. Our primary endpoint was progression free survival (PFS), defined as time from date of enrollment (SWOG) or registration (PRIMA) to date of progression or death from any cause. Overall survival (SWOG enrollment/PRIMA registration to date of death from any cause) was also evaluated. Kaplan-Meier survival curves were estimated, and differences in survival time by vitamin D status were assessed using the log-rank test. Results: The SWOG cohort included 183 pts enrolled and treated in centers across the US: 55% male, 96% Caucasian, and 30% age 60 or older. Pts largely had grade 1–2 FL (90%) advanced stage (68% stage IV) FL; only 16% were poor prognosis according to IPI. Median serum 25(OH)D was 31 ng/ml. After median follow-up of 5.4 years, pts with serum 25(OH)D < 20 ng/ml (insufficiency threshold per 2010 Institute of Medicine recommendations) had significantly inferior PFS (HR 2.00, p=0.011) and OS (HR 3.57, p=0.003) as compared to those with higher levels (analyses stratified by treatment trial and adjusted for IPI). The PRIMA subset cohort included pts primarily enrolled and treated in France and Belgium: 55% male, and 39% over age 60. The majority of these pts were high risk (91% Stage III/IV, 46% ≥3 by FLIPI, 34% with B symptoms). Surprisingly, the PRIMA serum 25(OH)D distribution was notably shifted in comparison to the SWOG cohort (median 17 ng/ml). As such, we conducted the analysis in this cohort with serum 25(OH)D dichotomized at both the median (17ng/ml) and first quartile (10 ng/ml). After median follow-up of 4.5 years, pts below the median (25(OH)D <17 ng/ml) that received R-CHOP induction (n=237) had significantly inferior OS (HR 3.8, p=0.02) as compared to those with higher levels. Moreover, when dichotomized at the first quartile (10 ng/ml), PFS and OS were significantly inferior for those with lower values (PFS HR 1.73, p=0.0086; OS HR 2.7, p=0.03). Conclusions: In this international collaborative study of newly diagnosed FL pts uniformly treated with chemotherapy and anti-CD20 therapy, we report a robust association between low vitamin D levels and FL outcomes in two independent cohorts. While the threshold for sufficiency with regard to FL outcomes will need to be further defined, and may vary by population and region, the observed prognostic significance of low vitamin D for FL in this study is surprisingly strong, with OS HRs indicating a magnitude of association at or greater than the individual FLIPI prognostic factors, which we currently rely upon clinically. Moreover, serum vitamin D is the first potentially modifiable factor to be associated with FL survival. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document